SCHEMBL1752008

SCHEMBL1752008

CC(C)(C)OC(=O)N(CCF)Cc1ccc(Cl)c(CNC2CC2)c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
NCOR2 Q9Y618 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
REN P00797 2/20 0.34
HTR4 Q13639 3/20 0.33
SSTR4 P31391 1/20 0.32
HTR5A P47898 1/20 0.32
SLC2A1 P11166 1/20 0.32
SUV39H2 Q9H5I1 1/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM1A O60341 2/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
HPGD P15428 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3087726 0.89 HDAC3 (0.39) HDAC3HDAC1HDAC2NCOR2SMN1; SMN2
SCHEMBL1750175 0.87 HDAC3 (0.35) HDAC3HDAC1HDAC2NCOR2SMN1; SMN2
SCHEMBL3080082 0.87 ALDH1A1 (0.37) HDAC3HDAC1HDAC2NCOR2SMN1; SMN2
SCHEMBL3092881 0.85 CACNA1B (0.36) SMN1; SMN2MEN1KMT2ARENSUV39H2
SCHEMBL1750787 0.83 SSTR4 (0.39) HDAC3HDAC1HDAC2NCOR2SSTR4
SCHEMBL3091571 0.83 NAMPT (0.37) HDAC3HDAC1HDAC2NCOR2SMN1; SMN2
SCHEMBL1751081 0.83 REN (0.42) HDAC3RENKDM1AHDAC8HDAC6
SCHEMBL1751232 0.82 HTR4 (0.34) SMN1; SMN2MEN1KMT2ARENHTR4
SCHEMBL3074250 0.81 CDK8 (0.37) SMN1; SMN2MEN1KMT2ARENHTR4
SCHEMBL1751416 0.79 REN (0.39) REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968720-B2 Secondary amines as renin inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2011-06-28 US disclosed
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES BEZENCON OLIVIER 2010-12-23 US disclosed
US-7799805-B2 Piperidine carboxylic acid amide derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-21 US disclosed
US-20090176823-A1 Secondary Amines as Renin Inhibitors ACTELION PHARMACEUTICALS LTD. (CH) 2009-07-09 US disclosed
EP-1981847-A1 SECONDARY AMINES AS RENIN INHIBITORS Actelion Pharmaceuticals Ltd. (CH) 2008-10-22 EP disclosed
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives ACTELION PHARMACEUTICALS LTD (CH) 2008-09-04 US disclosed
EP-1893578-A2 NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2008-03-05 EP disclosed
WO-2007088514-A1 SECONDARY AMINES AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2007-08-09 WO disclosed
WO-2006129237-A2 NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives REN, ACE, AGTR2 HDAC3 69/4885HDAC1 82/4885HDAC2 75/4885
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES REN, ACE, AGTR2 HDAC3 224/4885HDAC1 219/4885HDAC2 172/4885
US-20090176823-A1 Secondary Amines as Renin Inhibitors REN, ACE, AGTR1 HDAC3 2748/4885HDAC1 1714/4885HDAC2 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.